O'Donovan, Michael - Cardiff University

个人简介

After obtaining my undergraduate qualifications in Physiology (BSc) and Medicine (MBChB) at the University of Glasgow, I specialized in psychiatry. I began my research career in 1989 as an MRC Training Fellow when I developed novel methods for quantitating mRNA, used these to show alterations in the relative expression of genes encoding subunits of GABAA receptors was a mechanism that contributes the biology of benzodiazepine tolerance, and obtained a PhD in Molecular Pharmacology. 1992-1993, I was an MRC Travelling Fellow at the laboratory of David Housman at MIT where I was a member of The Huntington's Disease Collaborative Research Group. In 1993, I was appointed Senior Lecturer in the Department of Psychological Medicine, University of Wales College of Medicine, and was awarded a personal chair in Psychiatric Genetics in 1999. I have a broad interest in the molecular genetics and neurobiology of mental disorders and have held grants from many major funding bodies (MRC, Wellcome Trust, National Institute of Mental Health (USA), European Union) for molecular genetic studies of schizophrenia, bipolar disorder, dyslexia, ADHD, and Alzheimer’s disease. I am currently the Chair of the Schizophrenia Working Group of the Psychiatric Genomics Consortium.

研究领域

Genetic variation makes important contributions to the aetiology of all major psychiatric disorders. Recent advances in molecular genetic technology offer unprecedented opportunities to identify specific risk genes for these disorders, and to use these findings as the basis for understanding the molecular basis of these hitherto enigmatic disorders. I am interested in identifying genes that contribute to susceptibility to a wide range of psychiatric disorders including schizophrenia, bipolar disorder, ADHD, and Alzheimer’s disease, and exploiting to findings to understanding the pathophysiological processes by which susceptibility is conferred.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Clifton, N.et al. 2017. Schizophrenia copy number variants and associative learning. Molecular Psychiatry 22(2), pp. 178-182. (10.1038/mp.2016.227) pdf Cosgrove, D.et al. 2017. MiR-137-derived polygenic risk: effects on cognitive performance in patients with schizophrenia and controls. Translational Psychiatry 7(1), pp. e1012. (10.1038/tp.2016.286) pdf Riglin, L.et al. 2017. Schizophrenia risk alleles and neurodevelopmental outcomes in childhood: a population-based cohort study. The Lancet Psychiatry 4(1), pp. 57-62. (10.1016/S2215-0366(16)30406-0) pdf Lo, M.et al. 2017. Genome-wide analyses for personality traits identify six genomic loci and show correlations with psychiatric disorders. Nature Genetics 49(1), pp. 152-156. (10.1038/ng.3736) pdf Riglin, L.et al. 2017. Schizophrenia polygenic risk score and psychotic risk detection - authors' reply. The Lancet Psychiatry pdf Sims, R.et al. 2017. Rare coding variants in PLCG2, ABI3 and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics pdf Riglin, L.et al. 2016. Association of genetic risk variants with Attention-Deficit/Hyperactivity Disorder trajectories in the general population. JAMA Psychiatry (10.1001/ jamapsychiatry.2016.2817) Rees, E.et al. 2016. Analysis of intellectual disability copy number variants for association with schizophrenia. JAMA Psychiatry 73(9), pp. 963-969. (10.1001/jamapsychiatry.2016.1831) Thapar, A.et al. 2016. Psychiatric gene discoveries shape evidence on ADHD's biology. Molecular Psychiatry 21(9), pp. 1202-1207. (10.1038/mp.2015.163) pdf